Nurix Therapeutics (NRIX) EBT Margin: 2019-2025
Historic EBT Margin for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -1,094.77%.
- Nurix Therapeutics' EBT Margin fell 70651.00% to -1,094.77% in Q3 2025 from the same period last year, while for Aug 2025 it was -291.58%, marking a year-over-year increase of 2161.00%. This contributed to the annual value of -354.36% for FY2024, which is 16738.00% down from last year.
- Nurix Therapeutics' EBT Margin amounted to -1,094.77% in Q3 2025, which was down 1,029.43% from -96.93% recorded in Q2 2025.
- Nurix Therapeutics' 5-year EBT Margin high stood at -79.14% for Q2 2023, and its period low was -1,094.77% during Q3 2025.
- Moreover, its 3-year median value for EBT Margin was -305.38% (2025), whereas its average is -347.34%.
- Its EBT Margin has fluctuated over the past 5 years, first skyrocketed by 41,196bps in 2023, then crashed by 70,651bps in 2025.
- Over the past 5 years, Nurix Therapeutics' EBT Margin (Quarterly) stood at -509.17% in 2021, then crashed by 17,957bps to -688.74% in 2022, then skyrocketed by 41,196bps to -276.77% in 2023, then slumped by 16,392bps to -440.69% in 2024, then crashed by 70,651bps to -1,094.77% in 2025.
- Its last three reported values are -1,094.77% in Q3 2025, -96.93% for Q2 2025, and -305.38% during Q1 2025.